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A big challenge to the interpretation of genome-scale
sequence variation is prioritization of the variants that
might explain a particular phenotype. Most approaches
to this problem focus on the type of mutation, no matter
the gene, but common sense suggests that some genes
should be more tolerant to sequence variation than others.
If so, missense changes, for example, would not be equally
likely to cause a problem in all genes. Petrovski et al. pro-
pose a scoring strategy in which genes can be ranked on
the basis of their general tolerance to sequence variation.
The scores are based on data from the National Heart,
Lung, and Blood Institute Exome Sequencing Project,
which provides information on the common functional
variation in the general population. Supporting the valid-
ity of their scoring system, disease genes listed in Online
Mendelian Inheritance inMan have higher variation intol-
erance scores than do genes that have not been linked with
Mendelian disease. Flagging the genes that don’t tolerate
variationmight provide an additional piece of information
that could be useful for the interpretation of personal
genome sequences.
Petrovski et al. (2013). PLOS Genetics 9, e1003709.
Etiology Predicts Risk in Hypertrophic
Cardiomyopathy
A variety of underlying issues can lead to hypertrophic car-
diomyopathy and it is plausible that the course of disease
depends on the etiology. Knowing which patients are at
the highest risk of a poor outcome could shift clinical man-
agement, but unfortunately, few data exist in pediatric
samples to stratify patients in this way. Recent longitudinal
data on more than 1,000 patients from the Pediatric Car-
diomyopathy Registry address this gap. The children
with the highest risk of death or heart transplant at two
years of age were those with an underlying inborn error
of metabolism; those with the best outcomes were those
diagnosed at over one year of age with idiopathic hyper-
trophic cardiomyopathy. On top of these subgroups, addi-
tional factors, such as weight, the presence of congestive
heart failure at diagnosis, and the left ventricular septal
thickness could further stratify the subgroups according
to risk. These data could be used to identify those affected
children who need early evaluation for heart transplant.
Lipshultz etal. (2013).TheLancet.PublishedonlineSeptember
3, 2013. http://dx.doi.org/10.1016/S0140-6736(13)61685-2.1Department of Human Genetics, Emory University School of Medicine, Atlan
*Correspondence: kgarber@genetics.emory.edu
http://dx.doi.org/10.1016/j.ajhg.2013.09.007. 2013 by The American Societ
The AmericImproved Learning andMemory in a Down Syndrome
Mouse Model
Individuals with Down syndrome have a smaller cere-
bellum—the relevant precursor cells are less responsive to
Sonic hedgehog (Shh), which is the major mitogen for
these cells. This led Roger Reeves and his colleagues to
explore whether a Shh agonist could stimulate cell prolifer-
ation in the brain and alter the course of the condition.
Their previous work suggested that treatment of affected
mouse pups at birth normalized the number of granule
cell precursors in the cerebellum, but it was unclear
whether the Shh agonist would have an effect long-term.
They have now followed these mice to adulthood after
this single perinatal agonist injection and report that the
cerebellar structure is normalized, the performance of the
mice in certain learning and memory tasks is improved,
and there is some rescue of NMDA-dependent synaptic
plasticity. Because Shh is such an important regulator of
several developmental pathways, the authors urge caution
before this approach is tested in people.
Das et al. (2013). Science Translational Medicine 5,
201ra120.
Wait until I Get My TALENs into You
Transcription activator-like effector nucleases, or TALENs,
are bipartite enzymes that have a specific, engineerable
DNA-binding domain coupled with a non-specific DNA-
cleavage domain. By tweaking the DNA binding specificity,
scientists can use these molecular scissors to precisely
manipulate the genome. But could they also use them to
get rid of a problematic DNA sequence? Becausemitochon-
drial mutations are often heteroplasmic—they are found in
the presence of wild-type mitochondria—Bacman et al.
wondered whether they could use TALENs to specifically
eliminate the mutant mitochondria from cells but leave
the wild-type mitochondria intact. TALENs must dimerize,
a feature that the researchers exploited in their design. In a
proof-of-principle, they targeted the most common patho-
genic mtDNA deletion, which is 5 kb. Each monomer of
this TALEN recognizes the sequence that flanks this dele-
tion, and only if the deletion is present will the bound
monomers be close enough to dimerize and cleave the
DNA. In a cell line heteroplasmic for this deletion, the ratio
of wild-type to mutant mtDNA increased in cells that con-
tained both halves of the TALEN. An increase in wild-type
mtDNA levels compensated for a transient decrease in totalta, GA 30322, USA
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mtDNA levels. The mitoTALEN approach also works when
a point mutation is targeted. In this case, one of the TALEN
monomers binds only to the mutant sequence, yielding
allele-specific cleavage that alters heteroplasmy and
rescues complex I activity in cells heteroplasmic for the
mutation.
Bacman et al. (2013). Nature Medicine 19, 1111–1113.
Common Risks for a Rare Disorder
The cardiac arrhythmia Brugada syndrome is a rare disor-
der that can cause sudden cardiac death. Although several
genes have been implicated in the syndrome, the only one
that is known to account for a significant fraction of cases
is SCN5A. Despite the fact that this is generally thought of
as an autosomal-dominant disorder, many people with a590 The American Journal of Human Genetics 93, 589–590, Octoberpathogenic mutation have no clinical features, even by
echocardiogram. This left Bezzina et al. scratching their
heads and wondering whether additional genetic variation
might contribute to the phenotype. Their genome-wide as-
sociation study implicates common variation in SCN5A,
SCN10A, and HEY2 as contributing to Brugada syndrome.
The cumulative effect of risk alleles at these three loci is
quite striking: the authors found an odds ratio of more
than 21 in individuals withmore than four risk alleles, sug-
gesting that common variation might contribute signifi-
cantly to risk of this rare syndrome. The fact that ~1.5%
of Europeans are expected to carry this many risk alleles
means that there is still more to learn about the etiology
of Brugada syndrome.
Bezzina et al. (2013). Nature Genetics 45, 1044–1049.This Month in Our Sister JournalsHeterozygosity Estimates from Low-Coverage
Sequence Data
Bryc et al. developed a method whereby they were able to
estimate heterozygosity from low-coverage sequence data.
A reference panel is required for this method, but the het-
erozygosity estimates are independent of the size and
composition of the panel, which relaxes the requirements
for this reference. The method manages low-coverage data
well and, using this type of data, provides heterozygosity
estimates similar to those based on higher-coveragesequences. The authors use this method to estimate rates
of heterozygosity for 11 humans from all over the world.
Complicating things is the fact that estimates of het-
erozygosity are linked to the local sequence coverage:
areas of lower and higher sequence coverage have
higher estimated heterozygosity than those with average
coverage. A set of filters at least partially corrects for this
confounder.
Bryc et al. (2013). Genetics. Published online August 9,
2013. http://dx.doi.org/10.1534/genetics.113.154500.3, 2013
